News
Christina Aguilera launches sexual wellness brand to ‘shift the narrative’ around female sexuality
The singer wants to champion the brand’s mission to create an open dialogue around sexual wellness
Christina Aguilera has been named the co-founder and chief brand advisor of the sexual wellness brand Playground.
The Grammy Award-winning singer will be working alongside Playground co-founder and CEO, Catherine Magee, and co-founder and chief product officer, Sandy Vukovic, to reduce stigma and improve sexual wellness for women through “ground-breaking” intimacy products.
Six out of ten women struggle with arousal issues and sexual discomfort, according to Playground.
However, as women invest more intentionally in their sexual experiences, they will see improvement in mood, health and their intimate relationships.
Aguilera has always used her voice to reduce the stigma around female sexuality, and in her role with the San Francisco-based start-up, she wants to further champion the brand’s mission to create an open dialogue around sexual wellness while keeping the female perspective at the forefront of the business.
“I continue to encourage women to feel empowered while owning every aspect of themselves, and to treat sexual wellness as part of a regular self-care routine,” the 42-year-old singer and co-founder said in a statement.

“The category has largely been driven by a male dominated business model, with few products designed from inception for female specific sexual pleasure and health needs.
“I’m thrilled to be part of a woman-owned business, and building a brand where women can recognise Playground as a product that is speaking to them with an informed perspective.”
Playground co-founder and CEO, Catherine Magee, said: “What’s been missing in the overall health and wellness conversation is the role of sexual health. Christina is the perfect voice to champion female sexuality.
“She has always proudly embraced her sexuality and has been unafraid to share it with her fans through her music or her own voice.
“As Playground’s chief brand advisor and co-founder, Christina has the platform to empower women to fully prioritise their sexual wellness.”
The brand wants to pioneer the growing sexual wellness category by launching the first and only FDA-approved personal lubricant to address women’s larger sexual pleasure needs.
With its debut collection, the company says it aims to “democratise” access to sexual wellness products and champion every woman to think of sexual wellness as an essential part of their everyday life.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







6 Comments